Butyrylcholinesterase Atypical Mutation in a Patient Undergoing Electroconvulsive Therapy

Samuel Bulteau1, François Etcheverrigaray, Marie Grall-Bronnec

  • 1ECT-TMS Unit, Addictology and Liaison Psychiatry Department Nantes University Hospital, Nantes, France Center for Evaluation and Information about Pharmacodépendences-Addictovigilance Clinical Pharmacology Department Nantes University Hospital, Nantes, France. etcheverrigaray@chu-nantes.fr Addictology and Liaison Psychiatry Department Nantes University Hospital, Nantes, France; and EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Nantes University, Nantes, France Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu-HME Nantes University Hospital, Nantes, France Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu-HME Nantes University Hospital, Nantes, France ECT-TMS Unit, Addictology and Liaison Psychiatry Department Nantes University Hospital, Nantes, France Center for Evaluation and Information about Pharmacodépendences-Addictovigilance Clinical Pharmacology Department Nantes University Hospital, Nantes, France; and EA 4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Nantes University, Nantes, France ECT-TMS Unit, Addictology and Liaison Psychiatry Department Nantes University Hospital, Nantes, France.

The Journal of ECT
|October 7, 2015
PubMed
Abstract

No abstract available in PubMed .

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
965
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
2.0K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
725